Ophthalmology

Researchers predicted that the inclusion of these additional factors—such as DME or RVO, and Medicare Advantage plan or private insurance use—would see cost savings in excess of $30 billion.

The researchers hope they will be able to use this template as a drug delivery solution for a variety of eye diseases.

Data is released from a pilot study of X4P-001-IO in combination with nivolumab in patients with clear cell renal cell carcinoma (ccRCC) who are non-responsive to the anti-PD-1 checkpoint inhibitor nivolumab alone.

The effectiveness of this nutritional prophylactic supplement is determined by genetic variation, making genotype group identification an important factor.

Those with the AMD showed greater expression of miRNA-150 than those without, offering evidence that miRNA-150 could be used as a potential biomarker—and drug target—for AMD.

Researchers are using hi-def retinal and neuroimaging techniques to elucidate the relationship between pathology in layers of the retina and downstream brain alterations.

Following the novel gene-editing tech's approval for the treatment of cancer last year, researchers at Roski Eye Institute are exploring its potential to treat ophthalmic disease.

Nanophotoswitches have demonstrated promising results in rats. Will they one day improve transduction in damaged eyes, and restore lost vision in humans?

The burden of ophthalmic disease is rising. How can ophthalmologists rise to meet it?

Intravitreal aflibercept injection showed early signs of activity for patients with moderately severe to severe nonproliferative diabetic retinopathy.

Researchers examined the role of RPE dysfunction in patients with AMD and found this discovery demonstrated hUTC’s potential therapeutic value in the treatment of AMD.

75% of patients with newly-diagnosed, treatment naïve DME received no treatment within 1 year of diagnosis.

The novel immune-based treatment IMCgp100 demonstrated a 1-year survival rate of 73% for patients with heavily pretreated, advanced uveal melanoma.

Voretigene neparvovec demonstrated sustained improvements in vision for patients with biallelic RPE65-mutation–associated inherited retinal disease.

The new indication will allow wearers to use the contacts for up to 6 nights and 7 days continuously.

Outcomes for patients with nAMD in the real-world were inferior to randomized controlled trials due to significant undertreatment.

Researchers hypothesized that making eye care screens free also reduced perceived value of the services.

The majority of eyes treated in the DRCR Protocol S study had resolved, stable or improved NV at each follow-up visit.

Brolucizumab, which could be given every 12 weeks, showed non-inferior improvements in BCVA when compared with aflibercept every 8 weeks.

Use of a 0.18 mg fluocinolone acetonide intravitreal insert effectively lowered the rate of uveitis recurrences and cumulative total recurrent episodes.

The algorithm identified PPL-HMA in 20% of eyes and was associated with a 2-3 fold increased risk of DR progression, development of PDR and receipt of intravitreal injections over 4 years.

The deep learning algorithm was tested on 71,000 images, and offers the potential to significantly increase the speed at which DR can be identified.

Eyes that received only anti-VEGF experienced significantly worse visual acuity from initial visit to final visit.

The solution to lower elevated intraocular pressure is approved 2 months ahead of the scheduled PDFUA date.

A fully automated artificial intelligence-based system could effectively classify function and potency of cell therapy.

Anti-VEGF and pan-retinal photocoagulation can be effective, but neither are "one-and-done" therapies. Physicians must be proactive about how they handle patients with PDR.

A wave of novel gene therapies is on the horizon as treatments for patients with retinitis pigmentosa.

While DEX implants improved BCVA in patients with DME, new data shows the improvement diminished over time.

New data has shown that using the anti-VEGF agent in patients with AMD that are older than 85 does not increase their risk of heart attack or stroke.

While some baseline characteristics may put patients at a greater risk of developing macular atrophy, ultimately, ranibizumab was not determined to raise that risk.